Dose relationship between GnRH antagonists and pituitary suppression

Human Reproduction

Volumn 11, Issue SUPPL. 3, 1996, Pages 133-147

  Rivier, J ^a   Jiang, G C ^a   Lahrichi, S L ^a   Porter, J ^a   Koerber, S C ^a   Rizo, J ^b   Corrigan, A ^a   Gierasch, L ^c   Hagler, A ^d   Vale, W ^a   Rivier, C ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d ACCELRYS INC   (United States)

Author keywords

Acyline; Azaline B; Betidamino acids; Drug design; GnRH antagonists

Indexed keywords

BUFFER; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HISTAMINE;

CONFERENCE PAPER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DEGRADATION; DRUG ELIMINATION; DRUG POTENCY; DRUG SOLUBILITY; HISTAMINE RELEASE; HORMONE INHIBITION; HYPOPHYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; STRUCTURE ACTIVITY RELATION;

EID: 13144281714     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/11.suppl_3.133     Document Type: Conference Paper

References (74)

1. Bagatell, C.J., Matsumoto, A.M., Christensen, R.B. et al. (1993) Comparison of a gonadotrophin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab., 77, 427-432.
2. Bergqvist, I.A. (1995) Hormonal regulation of endometriosis and the rationales and effects of gonadotrophin-releasing hormone agonist treatment: a review. Hum. Reprod., 10, 446-452.
3. Bhasin, S., Sikka, S., Fielder, T. et al. (1986) Hormonal effects of Ketoconazole in vivo in the male rat: mechanism of action. Endocrinology, 118, 1229-1232.
4. Bienstock, R.J., Rizo, J., Koerber, S.C. et al. (1993) Conformational analysis of a highly potent dicyclic gonadotropin-releasing hormone antagonist by nuclear magnetic resonance and molecular dynamics. J. Med. Chem., 36, 3265-3273.
5. Bock, M.G., DiPardo, R.M., Evans, B.E. et al. (1993) Development of 1,4-benzodiazepine cholecystokinin type B antagonists. J. Med. Chem., 36, 4276-4292.
6. Bock, M.G., DiPardo, R.M., Evans, B.E. et al. (1989) Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem., 32, 13-16.
7. Campen, C.A., Lai, M.-T., Kraft, P. et al. (1995) Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotrophin releasing hormone (GnRH) receptor antagonist 'Azaline B'. Biochem. Pharmacol., 49, 1313-1321.
8. Chandrasekaren, R., Lakshminarayanan, A.V., Pandya, U.V. and Ramachandran, G.N. (1973) Conformation of the LL and LD hairpin bends with internal hydrogen bonds in proteins and peptides. Biochim. Biophys. Acta, 303, 14-27.
9. Chary, V.R., Srivastava, S., Hosur, R.V. et al. (1986) Molecular conformation of gonadoliberin using two-dimensional NMR spectroscopy. Eur. J. Biochem., 158, 323-332.
10. Daneshdoost, L., Pavlou, S.N., Molich, M.E. et al. (1990) Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a GnRH antagonist. J. Clin. Endocrinol. Metab., 71, 92-97.
11. De, B., Plattner, J.J., Bush, E.N. et al. (1989) LH-RH antagonists: design and synthesis of a novel series of peptidomimetics. J. Med. Chem., 32, 2036-2038.
12. Deslauriers, R., Levy, G.C., McGregor, W.H. et al. (1975) Conformational flexibility of luteinizing hormone-releasing hormone in aqueous solution. A carbon-13 spin-lattice relaxation time study. Biochemistry, 14, 4335-4343.
13. Dhanoa, D.S., Bagley, S.W., Chang, R.S.L. et al. (1993a) Non-peptide angiotensin II receptor antagonists. I. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles. J. Med. Chem., 36, 4230-4238.
14. Dhanoa, D.S., Bagley, S.W., Chang, R.S.L. et al. (1993b) Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis and biological activity of N-substituted (Phenylamino) phenylacetic acids and acyl sulfonamides. J. Med. Chem., 36, 4239-4249.
15. Ditkoff, E.C., Cassidenti, D.L., Paulson, R.J. et al. (1992) The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am. J. Obstet. Gynecol., 165, 1811-1817.
16. Dutta, A.S. (1988) Luteinizing hormone-releasing hormone (LHRH) antagonists. Drugs of the Future, 13, 43-57.
17. Evans, B.E., Leighton, J.L., Rittle, K.E. et al. (1992) Orally active, nonpeptide oxytocin antagonists. J. Med. Chem., 35, 3919-3927.
18. Evans, B.E., Lundell, G.F., Gilbert, K.F. et al. (1993) Nanomolar-affinity, non-peptide oxytocin receptor antagonists. J. Med. Chem., 36, 3993-4005.
19. Freidinger, R.M., Veber, D.F., Perlow, D.S. et al. (1980) Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog. Science. 210, 656-658.
20. Gonzalez-Barcena, D., Buenfil, M.V., Procel, E.G. et al. (1994) Inhibition of luteinizing hormone. follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). Eur. J. Endocrinol. 131, 286-292.
21. Gupta, H.M., Talwar, G.P. and Salunke, D.M. (1993) A novel computer modeling approach to the structures of small bioactive peptides: the structure of gonadotrophin releasing hormone. Proteins: Structure, Function and Genetics, 16, 48-56.
22. Hall, J.E., Bhatta, N., Adams, J.M. et al. (1990) Variable tolerance of the developing follicle and corpus luteum to GnRH antagonist-induced gonadotrophin withdrawal in the human. J. Clin. Endocrinol. Metab., 72, 993-1000.
23. Haviv, F., Fitzpatrick, T.D., Nichols, C.J. et al. (1993) The effect of NMeTyrS substitution in luteinizing hormone-releasing hormone antagonists. J. Med. Chem., 36, 928-933.
24. Hoeger, C.A., Jiang, G.-C., Koerber, S.C. et al. (1996) Betide based strategy for the design of selective somatostatin analogs. In Hodges, P.K.R. (ed.), Proceedings of the 14th American Peptide Symposium, Columbus, Ohio, June 18-23, 1995. Mayflower Scientific Ltd, UK. pp. 635-636.
25. Karten, M.J. (1992) An overview of GnRH antagonists development: two decades of progress, In Crowley, W.F. Jr and Conn, P.M. (eds), Modes of Action of GnRH and GnRH Analogs. Springer Verlag, New York, pp. 277-297.
26. Karten, M.J., Hoeger, C.A., Hook, W.A. et al. (1990) The development of safer GnRH antagonists: strategy and status. In Bouchard, P., Haour, F., Franchimont, P. and Schatz, B. (eds). Recent Progress on GnRH and Gonadal Peptides. Elsevier, Paris. France, pp. 147-158.
27. Karten, M.J., Hook, W.A., Siraganian, R.P. et al. (1987) In vitro histamine release with LHRH analogs. In Vickery, B.H. and J.J. Nestor, J. (eds), LHRH and Its Analogs, Contraceptive and Therapeutic Applications, Part 2. MTP Press Ltd., Lancaster, Boston, The Hague, pp. 179-190.
28. Katritzky, A.R., Urogdi, L. and Mayence, A. (1989) Benzotriazole-assisted synthesis of monoacyl α-aminoglycines. J. Chem. Soc., Chem. Commun., 337-338.
29. Katritzky, A.R., Urogdi, L. and Mayence, A. (1990) Benzotriazole-assisted synthesis of monoacyl aminals and their peptide derivatives. J. Org. Chem., 55, 2206-2214.
30. Kawaguchi, K., Maruyama, T., Terasawa, I. et al. (1989) Structure of luteinizing hormone-releasing hormone bound to perdeuterated dodecylphosphocholine micelles as studies by 2D-NMR. Peptide Chem., 337-340.
31. Kettel, L.M., Murphy, A.A., Morales, A.J. et al. (1993) Rapid regression of uterine leiomyoma in response to long-term daily administration of GnRH antagonist. Fertil. Steril., 60, 642-646.
32. Kolp, L.A., Pavlou, S.N., Urban, R.J. et al. (1992) Abrogation by a potent gonadotropin-releasing hormone antagonist of the estrogen progesterone-stimulated surge-like release of luteinizing hormone and follicle-stimulating hormone in postmenopausal women. J. Clin. Endocrinol. Metab., 75, 993-997.
33. Kopple, K.D. (1981) On the location of β-turns. Biopolymers, 20, 1913-1920.
34. Kopple, K.D. (1983a) Nitroxyl-induced T1 relaxation rates as a probe of conformation in peptide hormones. Int. J. Pept. Protein Res., 21, 43-48.
35. Kopple, K.D. (1983b) Peptide backbone folding in LHRH and analogs. In Rich, D.H. and Gross, E. (eds), Peptides: Synthesis-Structure-Function, University of Wisconsin, Madison/Pierce Chemical Co, Rockford, IL, pp. 295-298.
36. 7]-LRF. Biochem. Biophys. Res. Comm., 63, 801-806.
37. Ljungqvist, A., Feng, D.-M., Bowers, C. et al. (1990) Antagonists of LHRH superior to amide: effective sequence/activity relationships. Tetrahedron, 46, 3297-3304.
38. Ljungqvist, A., Feng, D.-M., Hook, W. et al (1988) Antide and related antagonists of luteinizing hormone release with long action and oral activity. Proc. Natl Acad. Sci. USA. 85, 8236-8240.
39. Ljungqvist, A., Feng, D.-M., Tang, P.-F.L. et al. (1987) Design, synthesis and bioassays of antagonists of LHRH which have high antiovulatory activity and release negligible histamine. Biochem. Biophys. Res. Commun., 148, 849-856.
40. Lowe, J.A., III, Drozda, S.E., Snider, R.M. et al. (1992) The discovery of (2S,3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]- octan-3-amine as a novel. nonpeptide substance P antagonist. J. Med. Chem., 35, 2591-2600.
41. Lunenfeld, B. and Insler, V. (eds) (1993) GnRH Analogues. The State of the Art 1993. Parthenon Publishing Group, Carnforth, Lancaster, p. 156.
42. McGrath, G.A., Goncalvez, R., Udupa, J. et al. (1992) New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a GnRH antagonist. J. Clin. Endocrinol. Metab., 76, 1363-1368.
43. Momany, F.A. (1976a) Confbrmational energy analysis of the molecule, luteinizing hormone-releasing hormone. 1. Native decapeptide. J. Am. Chem. Soc., 98, 2990-2996.
44. Momany, F.A. (1976b) Conformational energy analysis of the molecule, luteinizing hormone-releasing hormone. 2. Tetrapeptide and decapeptide analogues. J. Am. Chem. Soc., 98, 2996-3000.
45. Monahan, M., Amoss, M., Anderson, H. and Vale, W. (1973) Synthetic analogues of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry, 12, 4616-4620.
46. Nikiforovich, G.V. and Marshall, G.R. (1993a) Conformation-function relationships in LHRH analogs. I. Conformation of LHRH peptide backbone. Int. J. Pept. Protein Res., 42, 171-180.
47. Nikiforovich, G.V. and Marshall, G.R. (1993b) Conformation-function relationships in LHRH analogs. II. Conformations of LHRH peptide agonists and antagonists. Int. J. Pept. Protein Res., 42, 181-193.
48. Pavlou, S.N., Rivier, J., Vale, W. and Kamilaris, T. (1990a) Clinical pharmacology of LHRH antagonists. In Vickery, B.H. and Lunenfeld, B. (eds), Precocious Puberty, Contraception and Safety Issues. Kluwer Academic Publishers, Dordrecht, pp. 127-131.
49. Pavlou, S.N., Veldhuis, J., Lindner, J. et al. (1990b) Persistence of concordant luteinizing hormone (LH), testosterone and a-subunit pulses following LH-releasing hormone antagonists administration in normal men. J. Clin. Endocrinol. Metab., 70, 1472-1478.
50. Qasmi, D., Rene, L. and Badet, B. (1993) An a-aminoglycine derivative suitable for solid phase peptide synthesis using Fmoc strategy. Tetrahedron Lett., 34, 3861-3862.
51. Rivier, J. (1993) Novel antagonists of GnRH: a compendium of their physicochemical properties. activities, relative potencies and efficacy in humans. In Lunenfeld, B. and Insler, V. (eds), GnRH Analogues. The State of the Art 1993. Parthenon Publishing Group. Carnforth, UK, pp. 13-26.
52. Rivier, J., Porter, J., Rivier, C. et al. (1986) New effective gonadotrophin releasing hormone antagonists with minimal potency for histamine release in vitro. J. Med. Chem., 29, 1846-1851.
53. Rivier, J., Koerber, S., Struthers, S. et al. (1988a) Design of active multicyclic gonadotrophin releasing hormone antagonists. In Marshak, D. and Liu, D. (eds), Proceedings of the Banbury Center Conference on Therapeutic Peptides & Proteins: Formulation. Delivery and Targeting, Cold Spring Harbor Press, New York, pp. 85-91.
54. Rivier, J., Kupryszewski, G., Varga, J. et al. (1988b) Design of potent cyclic gonadotrophin releasing hormone (GnRH) antagonists. J. Med. Chem., 31, 677-682.
55. Rivier, J., Koerber, S., Rivier, C. et al. (1990) Design, computer derived structure and biological activity of three bicyclic gonadotrophin releasing hormone (GnRH) antagonists. In Villafranca, J. (ed.). Current Research in Protein Chemistry, Academic Press, Seattle, pp. 273-281.
56. Rivier, J., Kupryszewski, G., Theobald, P. et al. (1991a) Two distinct approaches for the design of potent GnRH antagonists. In Lunenfeld, B. (ed.). Proceedings of the Second International Symposium on GnRH Analogues in Cancer and Hitman Reproduction, Geneva. Switzerland, November 7-10, 1990. Parthenon Publishing, Carnforth, UK, pp. 123-135.
57. ω-cyano modified guanidine moieties. Biochem. Biophys. Res. Commun., 176, 406-412.
58. Rivier, J., Porter, J., Hoeger, C. et al. (1992) Gonadotropin releasing hormone antagonists with Nω-triazolyl-ornithine, -lysine or -para-aminophenylalanine residues at positions 5 and 6. J. Med. Chem., 35, 4270-4278.
59. Rivier, J.E., Jiang, G., Porter, J. et al. (1995) GnRH antagonists: novel members of the azaline B family. J. Med. Chem., 38, 2649-2662.
60. Rivier, J.E., Jiang, G.-C., Simon, L. et al. (1996a) Betidamino acids: versatile and constrained scaffolds for drug discovery. In Hodges, P.K.R. (eds), Proceedings of the 14th American Peptide Symposium, Columbus, OH, June 18-23, 1995, pp. 275-277.
61. Rivier, J.E., Jiang, G.-C., Koerber, S.C. et al. (1996b) Betidamino acids: versatile and constrained scaffolds for drug discovery. Proc. Natl. Acad. Sci. USA, 96, 2031-2036.
62. Rizo, J., Koerber, S.C., Bienstock, R.J. et al. (1992a) Conformational analysis of a highly potent, constrained gonadotropin-releasing hormone antagonist. 2. Molecular dynamics simulations. J. Am. Chem. Soc., 114, 2860-2871.
63. Rizo, J., Koerber, S.C., Bienstock, R.J. et al. (1992b) Conformational analysis of a highly potent, constrained gonadotropin-releasing hormone antagonist. 1. Nuclear magnetic resonance. J. Am. Chem. Soc., 114, 2852-2859.
64. Roseff, S.J., Kettel, L.M., Rivier, J. et al. (1990) Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of GnRH and prosterone to late luteal phase women. Fertil. Steril., 54, 805-810.
65. Soules, M.R., Bremner, W.J., Dahl, K.D. et al. (1990) The induction of premature luteolysis in normal women-follicular LH secretion and corpus luteum function in the subsequent cycle. Am. J. Obstet. Gynecol., 164, 989-996.
66. Sprecher, R.F. and Momany, F.A. (1979) On the conformation of luteinizing hormone-releasing hormone, nuclear overhauser observations. Biochem. Biophys. Res. Commun., 87, 72-77.
67. Tenover, J.S., Dahl, K.D., Vale, W.W. et al. (1990) Hormonal responses to a potent gonadotrophin hormone-releasing antagonist in normal elderly men. J. Clin. Endocrinol. Metab., 71, 881-888.
68. ω-cyanoguanidino moieties on selected amino functions during SPPS. J. Am. Chem. Soc., 112, 9624-9626.
69. ω-cyano-homoarginine amino acids. American Chemical Society, Boston, Massachusetts, p.
70. ω-cyanoguanidino moieties. J. Med. Chem., 34, 2395-2402.
71. Tonelli, A.E. (1976) The effects of isolated N-methylated residues on the Conformational characteristics of polypeptides. Biopolymers, 15, 1615-1622.
72. Urban, R.J., Pavlou, S.N., Rivier, J.E. et al. (1990) Suppressive actions of a gonadotropin-releasing hormone (GnRH) antagonist on LH, FSH, and prolactin release in estrogen-deficient postmenopausal women. Am. J. Obstet. Gynecol., 162, 1255-1260.
73. Wessels, P.L., Feeney, J., Gergory, H. and Gormley, J.J. (1973) High resolution nuclear magnetic resonance studies of the conformation of the luteinizing hormone-releasing hormone (LH-RH) and its component peptides. J.C.S. Perkin, II, 1691-1698.
74. Williams, P.D., Ball, R.G., Bock, M.G. et al. (1994) Orally active, non-peptide oxytocin antagonists. In Hodges, R. and Smith, J. (eds). Peptides: Chemistry. Structure and Biology, Edmonton, Alberta, Canada, June 20-25, 1993. ESCOM Science Publishers B.V., Leiden, The Netherlands. pp. 275-277.